SEC Form 4 · accession 0001144204-15-062579
Inspyr Therapeutics, Inc. · NSPX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Craig A Dionne
Officer — CEO, CFO, President · Director · 10% Owner
Period of report
Nov 2, 2015
Accepted (ET)
Nov 3, 2015 · 8:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001421204
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 2, 2015 | C | 262,500 | $0.40 | A | 1,709,247 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible NoteF1 | $0.50 | Nov 2, 2015 | C | — | D | Dec 23, 2005 | Dec 31, 2050 | Common Stock | 87,500 | 0 | D |
| Convertible NoteF1 | $0.50 | Nov 2, 2015 | C | — | D | May 19, 2006 | Dec 31, 2050 | Common Stock | 100,000 | 0 | D |
| Convertible NoteF1 | $0.50 | Nov 2, 2015 | C | — | D | Dec 6, 2006 | Dec 31, 2050 | Common Stock | 75,000 | 0 | D |
Explanation of responses
- F1Disclosing the conversion of three outstanding convertible notes having an aggregate outstanding balance of principal and interest of $138,576.41. Reporting person has waived $33,576.41 of accrued interest as consideration for reducing conversion price of the notes from $0.50 to $0.40.